Ricardo Lleonart

Dr. Ricardo Lleonart

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in Genetic Analysis: Biomolecular Engineering
Verified
Journal Article
Closed access
Jose De La FuenteJose De La Fuente
Jose De La Fuente
MRManuel Rodrı́guez
Manuel Rodrı́guez
CMCarlos Montero
Carlos Montero
MRMiguel Redondo
Miguel Redondo
JGJosé Carlos Garcı́a-Garcı́a
José Carlos Garcı́a-Garcı́a
RLRicardo Lleonart
Ricardo Lleonart

1 March 1994 in Journal of Biotechnology
Verified
Journal Article
Closed access
Manuel Rodriguez-ValleManuel Rodriguez-Valle
Manuel Rodriguez-Valle
RRRoger Rubiera
Roger Rubiera
MPManuel Penichet
Manuel Penichet
RMRaquel Montesinos
Raquel Montesinos
JCJosé Cremata
José Cremata
Jose De La FuenteJose De La Fuente
Jose De La Fuente

16 March 2018 in Molecules
Verified
Journal Article
Open access
PDF file
CGCarolina De la Guardia
Carolina De la Guardia
DSDavid Stephens
David Stephens
HDHang T. Dang
Hang T. Dang
MQMario Quijada
Mario Quijada
OLOleg Larionov
Oleg Larionov
RLRicardo Lleonart
Ricardo Lleonart
Dengue virus causes dengue fever, a debilitating disease with an increasing incidence in many tropical and subtropical territories. So far, there are no effective antivirals licensed to treat this virus. Here we describe the synthesis and antiviral activity evaluation of two compounds based on the quinoline scaffold, which has shown potential for the development of molecules with various biological activities. Two of the tested compounds showed dose-dependent inhibition of dengue virus serotype 2 in the low and sub micromolar range. The compounds 1 and 2 were also able to impair the accumulation of the viral envelope glycoprotein in infected cells, while showing no sign of direct virucidal activity and acting possibly through a mechanism involving the early stages of the infection. The results are congruent with previously reported data showing the potential of quinoline derivatives as a promising scaffold for the development of new antivirals against this important virus.

1 April 1995 in Veterinary Parasitology
Verified
Journal Article
Closed access
Manuel Rodriguez-ValleManuel Rodriguez-Valle
Manuel Rodriguez-Valle
MPM.L. Penichet
M.L. Penichet
AMA.E. Mouris
A.E. Mouris
VLV. Labarta
V. Labarta
LLL. Lorenzo Luaces
L. Lorenzo Luaces
Jose De La FuenteJose De La Fuente
Jose De La Fuente

24 February 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ALAlejandro Llanes
Alejandro Llanes
CRCarlos Mario Restrepo
Carlos Mario Restrepo
GVGina Del Vecchio
Gina Del Vecchio
FAFranklin José Anguizola
Franklin José Anguizola
RLRicardo Lleonart
Ricardo Lleonart
Kinetoplastid parasites of the Leishmania genus cause several forms of leishmaniasis. Leishmania species pathogenic to human are separated into two subgenera, Leishmania (Leishmania) and L. (Viannia). Species from the Viannia subgenus cause predominantly cutaneous leishmaniasis in Central and South America, occasionally leading to more severe clinical presentations. Although the genomes of several species of Leishmania have been sequenced to date, only one belongs to this rather different subgenus. Here we explore the unique features of the Viannia subgenus by sequencing and analyzing the genome of L. (Viannia) panamensis. Against a background of conservation in gene content and synteny, we found key differences at the genomic level that may explain the occurrence of molecular processes involving nucleic acid manipulation and differential modification of surface glycoconjugates. These differences may in part explain some phenotypic characteristics of the Viannia parasites, including their increased adaptive capacity and enhanced metastatic ability.

20 September 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
AAAndreina Ayala
Andreina Ayala
ALAlejandro Llanes
Alejandro Llanes
RLRicardo Lleonart
Ricardo Lleonart
CRCarlos Mario Restrepo
Carlos Mario Restrepo
Leishmaniasis is a neglected tropical disease caused by parasites of the genus Leishmania. As approved human vaccines are not available, treatment and prevention rely heavily on toxic chemotherapeutic agents, which face increasing resistance problems. The development of effective vaccines against human leishmaniasis is of utmost importance for the control of the disease. Strategies that have been considered for this purpose range from whole-killed and attenuated parasites to recombinant proteins and DNA vaccines. The ideal vaccine must be safe and effective, ensuring lasting immunity through a robust IL-12-driven Th1 adaptive immune response. Despite some success and years of effort, human vaccine trials have encountered difficulties in conferring durable protection against Leishmania, a problem that may be attributed to the parasite’s antigenic diversity and the intricate nature of the host’s immune response. The aim of this review is to provide a thorough overview of recent advances in Leishmania vaccine development, ranging from initial trials to recent achievements, such as the ChAd63-KH DNA vaccine, which underscores the potential for effective control of leishmaniasis through continued research in this field.